



Abgenix to Present at Goldman Sachs Twenty-Fourth Annual Global Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--June 5, 2003--Abgenix, Inc. (Nasdaq:ABGX) today announced that it will present at the Goldman Sachs 24th Annual Healthcare Conference on Wednesday, June 11, 2003 at 2:40 p.m. PDT, 5:40 p.m. EDT. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com.

Raymond Withy, Ph.D., president and chief executive officer of Abgenix, will provide a business overview including a review of the ABX-EGF clinical data that was recently presented at the American Society of Clinical Oncology.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

Statements made in this press release about Abgenix's technologies, product development activities, collaborative arrangements and manufacturing activities, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, product manufacturing, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

CONTACT: Abgenix
Ami Knoefler, 510/284-6350 or 510/284-6605
Director, Corporate Communications

SOURCE: Abgenix